Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665108 | 0.83 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2KMT2A | |
| SCHEMBL32665500 | 0.78 | POLB (0.46) | CA2CA1CA12CA9GAA | |
| SCHEMBL2176443 | 0.78 | NPC1 (0.65) | CA2CA1CA12CA9GRK2 | |
| SCHEMBL23564738 | 0.77 | EPHX2 (0.57) | CA2CA1CA12SMN1; SMN2CA7 | |
| SCHEMBL20740269 | 0.75 | LMNA (0.68) | CA2CA1CA12CA9LMNA | |
| SCHEMBL4406319 | 0.75 | LMNA (0.68) | CA2CA1CA12CA9LMNA | |
| SCHEMBL20634610 | 0.75 | STS (0.44) | STSCA2CA1CA12CA9 | |
| SCHEMBL32665182 | 0.74 | KMT2A (0.47) | SMN1; SMN2GAANPC1KMT2AMEN1 | |
| SCHEMBL32665587 | 0.73 | TRPV1 (0.54) | LMNAGAAKMT2ATPSAB1MEN1 | |
| SCHEMBL28822072 | 0.73 | L3MBTL1 (0.64) | CA2CA1CA12GRK2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | STS 3493/4885CA2 3681/4885CA1 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.